Published in Cancer Weekly, February 8th, 2005
"Our study showed that patients with chronic hepatitis B responded to peginterferon alfa-2b, and achieved higher sustained response rates than is typically seen with any other antiviral treatment," said lead investigator Harry Janssen, MD, PhD, from the Erasmus Medical Center in Rotterdam, The Netherlands, where the international study was coordinated. "Based on...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.